邢唷>? ?e??  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdf?ghijklmnopqrstuvwxyz{|}~€Root Entry FC扯颒@揟€WorkbookbETExtDataSummaryInformation(@ ???!? 骥x??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? g2蓘\p Windows (u7b Ba==餤)8X@"1喪媅SO1喪媅SO1喪媅SO1喪媅SO1喪wiSO1喪wiSO1.Times New Roman1喪wiSO1喪wiSO1喪wiSO1喪媅SO1喪媅SO1 喪媅SO1h8喪媅SO1,8喪媅SO18喪媅SO18喪媅SO1喪媅SO1 喪媅SO1喪媅SO1喪媅SO14喪媅SO1 喪媅SO1喪媅SO1 喪媅SO14喪媅SO1<喪媅SO1?喪媅SO1>喪媅SO1喪媅SO1.Times New Roman1喪wiSO1 喪wiSO1h喪Rz個{h媅1"喪 N媅_GB2312"?#,##0;"?\-#,##0"?#,##0;[Red]"?\-#,##0"?#,##0.00;"?\-#,##0.00#"?#,##0.00;[Red]"?\-#,##0.007*2_ "?* #,##0_ ;_ "?* \-#,##0_ ;_ "?* "-"_ ;_ @_ .))_ * #,##0_ ;_ * \-#,##0_ ;_ * "-"_ ;_ @_ ?,:_ "?* #,##0.00_ ;_ "?* \-#,##0.00_ ;_ "?* "-"??_ ;_ @_ 6+1_ * #,##0.00_ ;_ * \-#,##0.00_ ;_ * "-"??_ ;_ @_ \$#,##0_);\(\$#,##0\)\$#,##0_);[Red]\(\$#,##0\) \$#,##0.00_);\(\$#,##0.00\)% \$#,##0.00_);[Red]\(\$#,##0.00\)?  ?  ?  ?  ?  ?  ?  ?  ?  ?  ?  ?  ?  ?  ?   ?  ?-  ?*  ?.  ?  ?/  ?,  ?  ?  ?.  ?,  ?3 ? ? ? ?$ ?1 ?4  ? ? ? @ @ ? @ @ ? @ @ ? ?-  ? ? ?* ?a@ >  ,?  *? ?  ?攆f7 ? ? ?`@ @  +?  )? ?> ? ?9 ?$ ?1 ?5 ?+ ? ? / ?  ?   x  x x x x  x  x x !x x x x x x@ @  x@ @  x@ @ x@ @ |@ @  x@ @ x@ @  x@ @  |@ @ |@ @  x@ @  x@ @  x@ @  @ @  x@ @  x@ @ x@ @  "x@ @  #x@ @  |@ @ 0@  0 @  x@ @  ||e錡蛚-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}-} .00\)_ *}-} .00\)_ *}-} .00\)_ *}-} .00\)_ *}-}.00\)_ *}-}.00\)_ *}-}.00\)_ *}A}.00\)_ *df;_ @_ }A}.00\)_ *df;_ @_ }A}.00\)_ *df;_ @_ }A}.00\)_ *df;_ @_ }A}.00\)_ *df;_ @_ }A}.00\)_ *df ;_ @_ }A}.00\)_ *蘈;_ @_ }A}.00\)_ *蘈;_ @_ }A}.00\)_ *蘈;_ @_ }A}.00\)_ *蘈;_ @_ }A}.00\)_ *蘈;_ @_ }A}.00\)_ *蘈 ;_ @_ }A}.00\)_ *13;_ @_ }A}.00\)_ *13;_ @_ }A}.00\)_ *13;_ @_ }A}.00\)_ *13;_ @_ }A} .00\)_ *13;_ @_ }A}!.00\)_ *13 ;_ @_ }-}".00\)_ *}-}#.00\)_ *}A}$.00\)_ *;_ @_ }A}%.00\)_ *;_ @_ }A}&.00\)_ *?;_ @_ }-}'.00\)_ *}A}(.00\)_ *俏;_ @_ }-}).00\)_ *}(}* .00\)_ *}A}+a.00\)_ *骑?;_ @_ }U},.00\)_ *;_ @_  }-}-.00\)_ *}-}..00\)_ *}}/鷠.00\)_ *蝌?;_ @_    }}0.00\)_ *ゥ?;_ @_ ??? ??? ??? ???}-}1.00\)_ *}-}2.00\)_ *}A}3鷠.00\)_ *€;_ @_ }-}4.00\)_ *}-}5.00\)_ *}A}6.00\)_ *;_ @_ }A}7.00\)_ *;_ @_ }A}8.00\)_ *;_ @_ }A}9.00\)_ *;_ @_ }A}:.00\)_ *;_ @_ }A};.00\)_ * ;_ @_ }A}<渆.00\)_ *霚;_ @_ }}=???.00\)_ *蝌?;_ @_ ??? ??? ??? ???}}>??v.00\)_ *虣;_ @_    }-}?€€.00\)_ *}}@.00\)_ *?;_ @_ 膊? 膊? 膊? 膊?}<}A.00\)_ *?;_ }<}B.00\)_ *?;_ }P}F.00\)_ *?;_ 膊? }(}G.00\)_ *}(}H.00\)_ *}(}I.00\)_ *}(}K.00\)_ *}(}L.00\)_ *}<}M.00\)_ *?;_ }(}N.00\)_ *}(}O.00\)_ *}(}R.00\)_ *}(}T.00\)_ *}(}U.00\)_ *}(}W.00\)_ *}(}X.00\)_ *}<}Y.00\)_ *?;_ }(}Z.00\)_ *}(}[.00\)_ *}(}\.00\)_ *}(}^.00\)_ *}<}_.00\)_ *?;_ }<}`.00\)_ *?;_ }-}b.00\)_ *}-}c.00\)_ *}(}d.00\)_ *!20% - :_寚eW[湗r 1O20% - :_寚eW[湗r 1 df苕? %!20% - :_寚eW[湗r 2O"20% - :_寚eW[湗r 2 df蜍? %!20% - :_寚eW[湗r 3O&20% - :_寚eW[湗r 3 df腭? %!20% - :_寚eW[湗r 4O*20% - :_寚eW[湗r 4 df溥? %!20% - :_寚eW[湗r 5O.20% - :_寚eW[湗r 5 df陬? %!20% - :_寚eW[湗r 6O220% - :_寚eW[湗r 6  df? %!40% - :_寚eW[湗r 1O40% - :_寚eW[湗r 1 蘈柑? %!40% - :_寚eW[湗r 2O#40% - :_寚eW[湗r 2 蘈娓? %!40% - :_寚eW[湗r 3O'40% - :_寚eW[湗r 3 蘈劁? %!40% - :_寚eW[湗r 4O+40% - :_寚eW[湗r 4 蘈汤? %!40% - :_寚eW[湗r 5O/40% - :_寚eW[湗r 5 蘈忿? %!40% - :_寚eW[湗r 6O340% - :_寚eW[湗r 6  蘈? %!60% - :_寚eW[湗r 1O 60% - :_寚eW[湗r 1 13暢? %!60% - :_寚eW[湗r 2O$60% - :_寚eW[湗r 2 13跂? %!60% - :_寚eW[湗r 3O(60% - :_寚eW[湗r 3 13淖? %!60% - :_寚eW[湗r 4O,60% - :_寚eW[湗r 4 13睜? %! 60% - :_寚eW[湗r 5O060% - :_寚eW[湗r 5 13捦? %!!60% - :_寚eW[湗r 6O460% - :_寚eW[湗r 6  13? %"€~vR詋 #h槝+h槝 I}%$h槝 1=h槝 1 I}%O伣%h槝 2=h槝 2 I}%O伣&h槝 3=h槝 3 I}%?Э?'h槝 4/h槝 4 I}%(頬5頬 俏 %€+8^膲 %)8^膲 2/8^膲 2 %*€(厤  +}Y5}Y 骑? a% ,Gl;`GGl;` %O伣O伣-€'^.€ '^[0] /梴o梴 蝌? 鷠% 0纇錱USCQ搹eQo搹eQ 虣 ??v% ?€ 5 騗繈顣剉厤 €€% @鑜蕬^ 鑜蕬 ?膊?膊?膊? 膊?6TableStyleMedium9` 她葉HrVVT>_antibioticInducedPseudomembranousEnterocolitisClostridSection<._ectopicPregnancySection<! ; 8"_generalizedAnxietyDisorderSection<T>_majorDepressiveDisorderTreatmentResistantInCombinationSection<9#_obsessiveCompulsiveDisorderSection<T>_ovarianCancerAdvancedInCombinationWithCarboplatinForPaSection<+_panicDisorderSection<;%_premenstrualDysphoricDisorderSection<g Do兞T酧o`厤魦ffN匭筟漁nc MicromedexR?uT+RTBR媁膲f甠\ NY@垺{巔L1.齎FDA騗yb芉N謡畍(嵗o }T€T(u嶯籰梪b篘>f甠\ NY@垺{巔 2. 0-NNS螛n舥f[Bg譥 02011t^4g,{15wS,{4g 0>f甠\ NY@垺{巔蕥璭蔛籰梪cWS 0檒)R鷢蚐擽\P25mg鹼邁'`慹黵畊(u嶯{弸W  50-100 mg/d\1.齎FDA*gyb芉檒)R鷢(u嶯籰梪b篘慹黵畊 2.-NNS;Sf[O 04N奮蕥梪cWS畍舥N'`舥R孮 0 3. 0-NNS螛n舥f[Bg譥 02010t^5g,{14wS,{5g 0鹼邁'`慹黵畊蕥璭蔛籰梪cWS 0孨2u蘏蛝y,_l_緩;NeY.ls^峇nfPN5mg緗^yR聢莡 13-17乗R\t^3w嵥YBR蠎:N2.5-5mg/d 錘2.5-5mgE^瀀螿 顅hBR蠎:N10mg/d g'YBR蠎:N20mg/da1.齎FDA騗yb芉eY.ls^鉙gBR媁(u嶯籰梪13-17乗?Q鍅緗^yR聢莡 2.-NNS;Sf[O 0緗^yR聢莡2柣lcWS 0,S琋'Yf[;Sf[鶴Hr>y,俹侞Nl堾l~vO銐20mg 8乗蔛錘 N?Q鍅R\t^w嵥YBR蠎10mg/d, NhTT瀀髞20mg/d]1.齎FDA騗yb芉l堾l(u嶯8乗蔛錘 N?Q鍅蛻慴翋莡剉籰梪 2.-NNS;Sf[O 0慴翋湒峹2柣lcWS 0,S琋'Yf[;Sf[鶴Hr>y,_l_緩;N)R鵚n魚``$GrBRa$鉙g瞞`$2mg a$30mg: 30ml13乗蔛錘 N?Q鍅)w嵥YBR蠎0.5mg/d, 24hT蟢)Y颯瀀燫0.5b1mg 俌€譙颯瀀髞3mg/dZ1.齎FDA騗yb芉)R鵚n?u嶯13乗蔛錘 N?Q鍅緗^yR聢莡剉籰梪 2.-NNS;Sf[O 0緗^yR聢莡2柣lcWS 0,S琋'Yf[;Sf[鶴Hr>y,俹侞N]x飩0Ws^躡癳 T 胈踰歔 `$蕬Gr a$剠渷c圙r `$30mg a$10mg鳀鷭舥10-20mg tid愂 b30-60mg qd蕬 €1.齎FDA*gyb芉]x飩0Ws^(u嶯籰梪b篘鳀鷭舥 2.-NNS;Sf[O 04N奮蕥梪cWS螛n舥R孮 0 3.-NNS;Sf[O 04N奮蕥梪cWS紆踰f[R孮 04. 0瀃(u畍舥'`舥籰梪f[ 0,{ NHr ,S琋'Yf[;Sf[鶴Hr>y,1gf[彋;N 5. 0-N齎4N奮畍舥f[ 0,_l蟼褃f[€b/g鶴Hr>y,u崹 `$蕬Gr a$蕬Gr奩 Zg貧@垕SU[嘫蕬Gr30mg,qd 蕬Gr10mg,tid-qidO1.齎FDA*gyb芉]x飩0Ws^蕬Gr0]x飩0Ws^蕬Gr(u嶯奩 Zg貧@垕S 2.4N奮蕥梪cWS-嘫褃R孮 3. 0嘫褃f[ 0,{kQHr ,篘lkSu鶴Hr>y,"宐_,邆噀=N;N/l檒fW褃 }歂剠渷c圙r0.1g謡?\舥線舥w嵥YBR蠎50mg/d 9hnc@垕S颯瀀蠎髞100mg/d1.齎FDA騗yb芉/l檒fW(u嶯籰梪b篘謡?\舥線舥 2. 02012 ADA謡?\舥蕥梪cWS 0 3. 0匭褃f[ 0,{孨Hr,篘lkSu鶴Hr>y,媠 T€;N 4. American Diabetes Association.Standards of medical care in diabetes--2012.Diabetes Care. 2012,35(1):S11-63Class I堻hR@lwc鷭魚100mg 2媁謡?\舥剉籰梪T€T(uo100mg qd<1.齎FDA騗yb芉堻hR@l(u嶯b篘2媁謡?\舥USobT€T(uo儎v籰梪 2. 04N奮匭R蘬f[ 0, Nwm褃f[€b/g鶴Hr>y H柖[&O;N Category A簢匭o塠SO`$GrBR: 20mg a$鰛蔞BR:< 20mg鋟畊鉙g ╟P傿R蠎:N cSO蛻蟢錯1-2mg/kgT1.齎FDA*gyb芉簢匭o?u嶯籰梪b篘鸞8^鋟畊 2.-NNS;Sf[O 04N奮蕥梪cWS" 畍舥N'`舥R孮 0 3. 0瀃(u畍舥'`舥籰梪f[ 0,{ NHr ,S琋'Yf[;Sf[鶴Hr>y,1gf[彋;N猅筓珒yr~偩廝NsN弫 250mg:12.5mg鶺昢苸迉Lv Y(u awMR俶筨Y 蟢hT擭!k c韣6hT o僫r擽\PYu畍h坆?\鰁@1.齎FDA騗yb芉5%剉猅筓珒yro弿?u嶯籰梪b篘Emh垊v畍鶺昢苸迉Lv 2. 0畍'`舥f[ 0,{8Hr ,篘lkSu鶴Hr>y  _f[決;N錯IQ'`覊S舥!Y(u awMR俶筨Y 蟢hT$N!k c韣16hT o僫r擽\PYu畍h坆?\鰁@1.齎FDA騗yb芉猅筓珒yro弿?u嶯籰梪b篘錯IQ'`覊S舥 2. 0瀃(u畍舥'`舥籰梪f[ 0,{ NHr ,S琋'Yf[;Sf[鶴Hr>y,1gf[彋;N鬩)RfUS梑偙籕r^墊垟 潃鹹i梑抍蚐擽剉剺220mg iv /gMR2h蔛/gT,{踁)Y齎FDA*gyb芉鬩)RfUS梑(u嶯剺2b篘潃鹹i抍蚐擽慴翋RNl堾lT€T籰梪蛻莡慴翋莡鰁w嵥YBR蠎5mg qn 颯宼e髞5-20mg qn Nl堾lT€T籰梪b篘蘏鴙慴翋莡鰁w嵥YBR蠎5mg qn 颯宼e髞5-12.5mg qn6 齎FDA騗yb芉eY.ls^鉙gBR媁Nl堾lT€T(u嶯籰梪b篘蘏鴙慴翋莡0蛻慴翋莡 nf^t鬩梘PN^taS鰛蔞75mg謡?\舥hT鬡^y蟸舥豐 ^y蟸舥t'`紆踰4w嵥YBR蠎50mg tidg'YBR蠎颯瀀髞100mg tidCre"60mL/min  FO梪 z6R(WNhT匭S1.齎FDA騗yb芉nf^t鬩梘(u嶯籰梪b篘謡?\舥hT鬡^y蟸舥豐 2. 02010 NICE ^y蟸舥t'`紆踰o僫r籰梪cWS 0#k~v緩爛秐鰛蔞60mg 謡?\舥hT鬡^y蟸舥'`紆踰60mg qdO1.齎FDA騗yb芉衯x懄^m堾l(u嶯籰梪b篘謡?\舥hT鬡^y蟸舥豐'`紆踰 2. 02010 NICE ^y蟸舥t'`紆踰o僫r籰梪cWS 0kxU VdT巔莡'`爛舥2mg/kgd 髞\擽(u3-6*Ng01.齎FDA*gyb芉kxU VdT籰梪b篘巔莡'`爛舥 2.-NNS;Sf[O 04N奮蕥梪cWS坢S鹼邁緐舥R孮 0 Class a!a N銼 }3z颯酧 鑜\(u鄀虄墊+g墊垟 緰◤環秗絺迉Fg虄鴙sQ'`y侞l鉙g=e"18乗125mg qid 梪 z10)Y 18乗40mg/kgd R3-4!kg(u 梪 z7-10)Y ;`BR蠎N厤菑2gk1.齎FDA騗yb芉N銼 }(u嶯籰梪緰◤環秗絺迉Fg虄鴙sQ'`y侞l 2. 0齎禰梑甠uir籰梪cWS2012  0,篘lkSu鶴Hr>y,kSu钀;S?e鳶;NClass `!?W^簚≧ 佖欯垕S5-20mg tid 魰敄4-6\鰁01.齎FDA騗yb芉?W^椈l梪b篘簚≧ 佖殝S 2.McLaughlin VV, Archer SL, Badesch DB,et al.ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension[J]. J Am Coll Cardiol.2009,53(17):1573 619 3.Gali N1, Hoeper MM, Humbert M, et al.Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. European Heart Journal.2009,30(20):2493 537 4. 0-N齎;Sf[MR縧Bg譥 02011t^,{3wS,{2g 02010t^-N齎簚貧@垕S蕥籰cWS 0(l磏"}恖俧W2ml:15mg 鴢Y褃Kb/g剉剺2?uo 1000mg/)Y1000mg/)Y 魚c6)Y1.穇齎Hr(l磏"}恖俧W 剉魦ffN騗yb芉(l磏"}(u嶯b篘Kb/gT簚钀v^裇莡剉剺2?`籰梪 v^c鶴(u嶯蛻莡€剉剺2桍eBR蠎颯緩1g/d5d  2.FDA*gyb芉(l磏"}(u嶯b篘Kb/gT簚钀v^裇莡剉剺2?`籰梪 3. 0-NNS胈鴢@垺{Y褃Bg譥 02009t^,{8g 0鴢Y褃鬡Kb/gg簚钀v^裇莡2柣lN禰qQ茓 0 4.Refai M1, Brunelli A, Xium F,et al.Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy: a randomizes trial[J].Eur J Cardiothorac Surg. 2009 Mar;35(3):469-73.Class b!癳蕥璭剉Y裇'`託$v N0W^Xs|~gT€TH200mg/d awMRbZfT1h N0W^Xs|~gT€T籰梪28)Y :NN梪 z00W^Xs|~gBR蠎:N40mg/d R+R(W,{1-4,9-12, 17-20)Yg(u01.齎FDA騗yb芉檒)R鷢N0W^Xs|~gT€T籰梪癳蕥璭剉b篘Y裇'`託$v 2. 02017 NCCNY裇'`託$v4N奮瀃鯈cWS 0 3. 0-NNS匭褃Bg譥 02011t^10g,{50wS,{10g 0-N齎Y裇'`託$v蕥籰cWS2011t^頞  0 4. 0匭褃f[ 0,{NHr ,篘lkSu鶴Hr>y,F枍Q駛;NO鄐US梑塠魚@l鑜\BR`$100mg:4ml a$400mg:16ml鐍裇嶯t^劅鴙sQ'`臑慹豐'`剉 佨~渷癳u@垺{S籹僼SO匭鑜\1.25mg/0.05mlJ1.齎FDA*gyb芉O鄐US梑(u嶯籰梪鐍裇嶯t^劅鴙sQ'`臑慹豐'`剉 佨~渷癳u@垺{S 2. 02015齎;齎FDA騗yb芉)RfUS梑T€Tl緩蒪鑞孴痵鱴p扂€(u嶯籰梪b篘鈋€_*g蟸籰梪剉孴鈋€_蟸籰梪剉CD203?`ba'`薽鬩苸迉}v@埮u筓kxs^`^t穅$`$25mg a$100mg b$200mg c$300mg蘏鴙湒峹慴翋鴙%`'`gUSN籰梪Z,{1錯N!k50mg N錯N!k0,{2錯 N!k100mg N錯N!k0,{3錯 N!k200mg N錯N!k0,{4錯 N!k300mg N錯N!k0o僫rawMRg(u ╟P兿k錯g'YBR蠎300mg/d0齎FDA騗yb芉筓kxs^(u嶯b篘蘏鴙湒峹慴翋鴙%`'`gUSN籰梪&`$25mg a$100mg b$200mg c$300mgN硏xbN bx憼Tv^O(u 蘏鴙湒峹魚cg籰梪厪㏑(uo?魚c錯BR蠎:N400-800mg/d R$N!kg(u g'Y錯BR蠎:N800mg/d0-齎FDA騗yb芉筓kxs^(u嶯籰梪b篘N硏xbN bx憼Tv^O(u 蘏鴙湒峹魚cg籰梪厪㏑(uo 蘏鴙湒峹`!媁亷聄鴙%`'`g R\t^10-17乗 1400-600mg/d R$N!k髞 N!kg(uw嵥YBR蠎:N50 mg/d 蟢錯g'Y瀀燫BR蠎d"100mg0&齎FDA騗yb芉筓kxs^(u嶯籰梪R\t^10-17乗 蘏鴙湒峹`!媁亷聄鴙%`'`g 緗^yR聢莡^楐~cg  R\t^13-17乗 d,{N)YBR蠎:N50mg/d,{孨)Y:N100mg/d,{ N)Y200mg/d,{踁)Y300mg/d,{擭)Y400mg/dR2-3!k賬o ╟P傿R蠎400-800mg/d 錯BR蠎g貧:N800mg/d%齎FDA騗yb芉筓kxs^(u嶯籰梪R\t^13-17乗 緗^yR聢莡^楐~cg 蕬GrA,{N)YZf NBR蠎:N50mg/d ,{ N)YZf NBR蠎瀀燫:N150mg/d ╟P傿R蠎凈V150-300mg/d g'YBR蠎:N300 mg/d0齎FDA騗yb芉筓kxs^(u嶯籰梪b篘蛻莡慴翋厪㏑(uo `$GrBR a$鉙g瞞`$2mg a$30ml30mgd[靣莡-f纎鵣媁 5乗錘 N?Q鍅R\t^`0.5-3mg/d鵞嶯擭乗b錘 NSO蛻NO嶯20kg剉?Q鍅 w嵥YBR蠎:N0.25 mg/d b蟢)Y$N!k賬o僇Spe;`蠎擭乗b錘 NSO蛻'Y嶯20kg剉?Q鍅 w嵥YBR蠎:N0.5mg/d bJSpe;`蠎賬o?N!k0!齎FDA騗yb芉)R鵚n懟l梪5乗錘 N?Q鍅R\t^d[靣莡-f纎鵣媁 蘏鴙湒峹`!媁 10乗錘 N?Q鍅R\t^Aw嵥YBR蠎:N0.5mg/d hfwbZf N鉙g 宼eBR蠎N\嶯24\鰁 瀀燫BR蠎:N0.5-1.0mg/d g'YP栂憺X燫:N2.5mg/d0齎FDA騗yb芉)R鵚n懟l梪10乗錘 N?Q鍅R\t^蘏鴙湒峹`!媁Y壷N[~ } 1.5ml:60mg邩Lv75mg/m2 B1.齎FDA*gyb芉Y壷N[?u嶯籰梪b篘邩Lv 2. 02016 NCCN4Y垬Lv籰梪cWS 0 &T€T+}Ig噾S梪筫Hh鰁Y 佽l\剉╟P傿R蠎10 mg/kg 蟢2hT賬o?!k0 01.齎FDA*gyb芉O鄐US梑籰梪b篘l忹y'`sNz丩v 2. 02016 NCCNsNz丩v4N奮瀃鯈cWS 0`$100mg:4ml a$400mg:16ml 聰€o儖WY裇uS鈃Lv1.Y 亾忚l 10mg/kg 蟢$NhT賬oN!k0T€T+}Ig噾0Y詆詋f?峉ObXb蔿f穅蟢hT賬oN!k -N剉鸑aN蛓 2.Y 亾忚l 15mg/kg 蟢3hT賬oN!k0T€TXb蔿f穅蟢3hT賬oN!k 0 1.齎FDA騗yb芉O鄐US梑T€T+}Ig噾0Y詆詋f?峉ObXb蔿f穅-N剉鸑aN蛓(u嶯籰梪b篘KNMR譙菑N厤菑2gS梪剉聰€o儖WY裇uS鈃Lv0搹uSLvb烻裇'`y仠丩v 2. 02015 NCCNuS鈃LvS靊搹uSLv孴烻裇'`y仠丩v4N奮瀃鯈cWS,{孨Hr) 0 Y裇bl忹y'`玔垬Lv.15mg/kg Y 亾忚l 蟢3hT賬o?!k0T€T+}Ig噾孴z樎b+}Ig噾孴Xb蔿f穅-N剉鸑aN蛓0 1.齎FDA騗yb芉O鄐US梑T€T+}Ig噾孴z樎bT€T+}Ig噾孴Xb蔿f穅(u嶯籰梪b篘cEN'`0Y裇bl忹y'`玔垬Lv 2. 02016 NCCN玔垬Lv4N奮瀃鯈cWS,{NHr) 0 `$5mg a$10mg^踠'`&qQ啘枍x10mg/d NhTT颯燫髞20mg/d齎FDA騗yb芉~傴S塣憂fpQ籰梪b篘^踠'`&qQ啘枍x0W^Xs|~g`$GrBR a$鑜\瞞`$GrBR:0.75mg a$鑜\瞞:1ml:5mg 銐S梪o僫r@b魜UTTS梪MR20mg iv,S梪T8mg po,bid 魚c3)Yi1.齎FDA*gyb芉0W^Xs|~g籰梪銐b篘S梪o僫r@b魜UTT0 2. 02015NCCN4N奮瀃鯈cWS.凷mf<\ 0 <  3. 0-N齎縺$v籰梪鴙sQUTT2柣lcWS2014Hr 0m堾l `$30mg a$60mg魚寑踰30mg/d魚cNhT 瀀蠎髞60mg/d齎FDA騗yb芉m堾l(u嶯籰梪b篘魚寑踰?w嵥YBR蠎60mg/d,_N颯錘30mg/d魚cNhT 瀀蠎髞60mg/d6qT颯鐍韣瀀燫30mg/d g'YBR蠎N厤菑120mg/d齎FDA騗yb芉m堾l(u嶯籰梪^踠'`&qQ啘枍xba'`寑墍細踰'w嵥YBR蠎30mg/d籰梪NhT 瀀髞60mg/d魚c,g'YBR蠎N厤菑60mg/d齎FDA騗yb芉m堾l(u嶯籰梪b篘ba'`寑墍細踰!Te梪剉@\钀Zfgbl忹y'`^\苸迉簚Lv剉N縹籰梪 2. 02016 NCCN^\苸迉簚Lv4N奮瀃鯈cWS,{踁Hr  0+}Ig噾餷 }5ml:30mg玔垬Lv耂翂cWS021.齎FDA*gyb芉+}Ig噾(u嶯籰梪b篘玔垬Lv 2. 02016 NCCN玔垬Lv4N奮瀃鯈cWS,{NHr) 0 @\钀Zfg N颯Rdbl忹y'`剉饊z丩v T€T T壷N鑞\O:NN縹籰梪筫HhC100mg 鉙g qd zzyg(u髞\(W蹚邩MR1\鰁b蹚邩T$N\鰁g(u 0c韣(uo凈v0R緐舥蹚U\b鶴皊N齹€譙剉襨'`蚐擽0T€T T壷N鑞0I1.齎FDA騗yb芉凷mf<\T€T T壷N鑞(u嶯b篘@\钀Zfg0N颯Rdbl忹y'`饊z丩v剉N縹籰梪 2. 02016 NCCN饊z丩v4N奮瀃鯈cWS,{NHr  0|xfPOs|N聅3.5mgR籰WY苸迉薽鬩$vS1.齎FDA騗yb芉|xfPOs|T€TY ?RfUS梑0痵鱴p扂€0? }孴鉙g黮<\~g(u嶯籰梪b篘鈋€_*g蟸籰梪剉WY苸迉薽鬩$v 2. 02016 NCCN^桮Y褢薽鬩$v,{孨Hr  0墺YfUS梑1r臺 100mg:20ml@\钀b:S遅'`Zfg4Y垬钀逌秗苸迉Lv T€T>e梪j (W_薡>e梪MR剉NhT w嵥Y圢400mg/m2 Y 亾忚l120ming'Y搹鑜惁^:N10mg/min 0彇T剉>e梪g魰6-7hT  蟢hT圢250mg/m2 qw Y 亾忚l60ming'Y搹鑜惁^:N10mg/min 0 J K1.齎FDA騗yb芉墺YfUS梑T€T>e梪(u嶯b篘@\钀b:S遅'`Zfg4Y垬钀逌秗苸迉Lv剉R薡籰梪 2. 02015 NCCN4Y垬钀Lv4N奮瀃鯈cWS ,{NHr  0 "錘聰{|o僫r:N鶺@x剉S梪1Y%T剉Y裇bl忹y'`4Y垬钀逌秗苸迉Lv USo兓l梪w USo兓l梪0w嵥Y圢400mg/m2 Y 亾忚l120ming'Y搹鑜惁^:N10mg/min 0彇T蟢hT圢250mg/m2 qw Y 亾忚l60ming'Y搹鑜惁^:N10mg/min  c韣(uo凈v0R緐舥蹚U\b鶴皊N齹€譙剉襨'`蚐擽0  9 :1.齎FDA騗yb芉墺YfUS梑US(u嶯籰梪b篘錘聰{|o僫r:N鶺@x剉S梪1Y%T剉Y裇bl忹y'`4Y垬钀逌秗苸迉Lv 2. 02015 NCCN4Y垬钀Lv4N奮瀃鯈cWS ,{NHr  0 +@\钀Y裇bl忹y'`4Y垬钀逌秗苸迉Lv T€T錘聰{|o僫r:N鶺@x剉S梪孴5-FU\O:NN縹籰梪筫Hh (W_薡錘聰{|o僫r:N鶺@x剉S梪孴5-FU籰梪剉,{1)Y w嵥Y圢400mg/m2 Y 亾忚l120ming'Y搹鑜惁^:N10mg/min 0vQT蟢hT圢250mg/m2 qw Y 亾忚l60ming'Y搹鑜惁^:N10mg/min  c韣(uo凈v0R緐舥蹚U\b鶴皊N齹€譙剉襨'`蚐擽0 $ %N O1.齎FDA騗yb芉墺YfUS梑T€T錘聰{|o僫r:N鶺@x剉S梪孴5-FU(u嶯b篘@\钀Y裇bl忹y'`4Y垬钀逌秗苸迉Lv剉N縹籰梪 2. 02015 NCCN4Y垬钀Lv4N奮瀃鯈cWS ,{NHr  0 Class a!b HY緩聰eYHQ緩$ 蟢!k賬o?00mg/m2 蟢梪 z賬oN!k 髞\\Po?hTT蛻Y NN*N梪 z0 Y1.齎FDA*gyb芉HY緩聰(u嶯籰梪b篘P[玔垬Lv 2.錯,gPDMA騗yb芉HY緩聰(u嶯籰梪b篘P[玔垬Lv f TeY1r痚N鰛蔞BR20mg 苺S怢v 耂翂PDMA魦ffNC1.錯,gPMDA騗yb芉f TeY(u嶯籰梪b篘苺S怢v 2. 0-N齎瀃(uY褃Bg譥 02014t^1g,{34wS,{1g 0苺Lv蕥璭N籰梪-Y褃N禰qQ茓 0f珒U鷢倓n l忹y'`v`'`褳r }$v:1.齎FDA*gyb芉f珒U鷢(u嶯籰梪b篘l忹y'`v`'`褳r }$v 2. 02016 NCCN褳r }$v4N奮瀃鯈cWS,{孨Hr  0 `$80mg a$160mg 謡?\舥線舥€M?\藛}v80mg qd81.齎FDA*gyb芉,檒fW(u嶯謡?\舥線舥€M?\藛}v 2.Hollenberg NK et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007 Sep;25(9):1921-6 3.Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003 20ml0.1G;熃TLv墺YfUS梑垟 400mg/!k+1.齎FDA*gyb芉墺YfUS梑(u嶯;熃TLv 2. 02016 NCCN;熃TLv4N奮瀃鯈cWS 0噀蒪誰洀蕬鰛蔞 `$150mg a$75mgb篘蔪P`湒峹 4O gbN4O g^:WP`鏯莡)37.5 mg/d 魚cNhT. NhTT颯瀀髞75 mg/d g'YBR蠎22< 5mg/dClass I b篘>yP`鏯莡75mg/d20mg/d齎FDA騗蟸yb芉衯x^W堾l(u嶯^踠'`&qQ啘枍x R$OT擽纎湒峹齎FDA騗蟸yb芉衯x^W堾l(u嶯R$OT擽纎湒峹魚y, 齎禰o儀Q訷XTO 3.Chua ME, Escusa KG, Luna S, et al. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis[J]. Andrology. 2013;1:749-57.ClassIIbWy, -NNS;Sf[O漁魚珒鳶迾<\ `$2.5mg a$5mg9sNz丩vN漁墡fWT€TO(u (u嶯籰梪輣蟸T纎 }譙SO3?` Her24?` O(ueg騠Ub?枺愹fU1Y%崉v蹚U\'`sNz丩v€  10mg蟢錯N!k鉙g賬o兛1.齎FDA騗yb芉迾<\N漁墡fWT€TO(u (u嶯籰梪輣蟸T纎 }譙SO3?` Her24?` O(ueg騠Ub?枺愹fU1Y%崉v蹚U\'`sNz丩v€0 2. 0NCCNsNz丩vcWS 02016t^,{NHr 3. 0ABC2hQtZfgsNz丩vcWS 0 4. 0-N齎梑LvOSOsNz丩v蕥籰cWSN膲 02015t^Hr  P熒b塶?`$20mg a$40mg b$60mg c$80mg)w嵥YBR蠎40mg bid N Tg 颯9hnc梪HeN€譙'`宼e:N40-80mg bid#齎FDA騗蟸yb芉衯x慞熒b塶?u嶯籰梪b篘蘏鴙湒峹`!媁亷聄b鱩T秗` N硏xbN bx憼Tv^O(u 蘏鴙湒峹厪㏑(uo40-80mg bid N曅vbN bxT(u'齎FDA騗蟸yb芉衯x慞熒b塶?u嶯b篘蘏鴙湒峹剉厪㏑籰梪N曅vbN bxT(u ^)R蘐n?`$3mg a$6mg b$9mg R聢臽a'`湒峹w嵥YBR蠎6mg qd 顅hBR蠎3-12mg/d齎FDA騗蟸yb芉^)R蘐n?u嶯籰梪b篘R聢臽a'`湒峹 12-17乗R\t^>SO蛻<51kgw嵥YBR蠎3mg qd 顅hBR蠎3-6mg/d SO蛻>51kgw嵥YBR蠎3mg qd 顅hBR蠎3-12mg/d!齎FDA騗蟸yb芉衯x^W堾l(u嶯籰梪12-17乗R\t^緗^yR聢莡=`$25mg a$50mg b$75mg c$100mg d$150mgR聢臽a'`湒峹 USo兓l梪b€\O:NN bx憼斒S梑慴翋o儎v厪㏑(uo儤鷁畫€(W鷁藌€譙'`T w嵥Y籰梪枡錯鑜\,g罷234mg NhTT峇!k鑜\156mg MR2BRw嵥Y籰梪o僫r剉鑜\钀MOGW:N N覊寑0(W枡!k鑜\5hTT 9hnc€剉€譙臽礠孴/b梪He 魚cBR蠎颯(W78-234mg剉凈V匭 蟢g1!k 蟢g颯9hnc梪He孴€譙'`宼eBR蠎0,{2BRo僫rKNT 蟢g1!k鑜\剉钀MO颯錘:N N覊寑b纴寑0;齎FDA騗蟸yb芉説坕x^)R蘐n?u嶯籰梪b篘^踠'`&qQ啘枍xR聢臽a'`湒峹 USo兓l梪b€\O:NN bx憼斒S梑慴翋o儎v厪㏑(uo傭f梘(w嵥YBR蠎:N25mg qd 閑 NbZf Ng(u g(uNhT顅hBR蠎50-200mg/d齎FDA騗蟸yb芉衯傭f梘(u嶯籰梪b篘蔪P`湒峹 齎FDA騗蟸yb芉衯傭f梘(u嶯籰梪b篘R$OT擽纎湒峹蟸MR&qQ喦ug蟸hTg匭w嵥YBR蠎50mg qd g'YBR蠎150mg/d齎FDA騗蟸yb芉衯傭f梘(u嶯籰梪b篘蟸MR&qQ喦u Class II a>yP``莡(w嵥YBR蠎:N25mg qd 閑 NbZf Ng(u g(uNhT 顅hBR蠎50-200mg/d齎FDA騗蟸yb芉衯傭f梘(u嶯籰梪b篘>yP``莡/l]x夘lw嵥YBR蠎0.25mg bid 顅hBR蠎1-4mg/d齎FDA騗蟸yb芉/l]x夘l(u嶯籰梪b篘蔪P`湒峹 蒪珒 N闡#`$25mg a$50mg b$100mg N,偅`€籰梪MR2hT25mg/d KNT2hT50mg/d KNT1hT100mg/d g'YBR蠎200mg/d T(uN bx懀`€籰梪MR2hT25mg qod KNT2hT25mg/d KNT1hT50mg/d g'YBR蠎100mg/d T(uv戱孅[BR€籰梪MR2hT50mg/d KNT2hT100mg/d KNT1hT200mg/d KNT1hT300mg/d g'YBR蠎200mg/d齎FDA騗蟸yb芉蒪珒 N闡(u嶯籰梪蘏鴙湒峹I媁 餷S200mg/m2/錯 蟢錯N!k qQ5)Y 6qT\Po?3)Y0NCCN褳r }$v籰梪cWS2016 V2S梪鴙sQUTT( `$ 10mg/!k d1-4貧魜T筫Hh  a$10mg/!k d1-3-N魜T筫Hh   !1NCCN bkTcWS 2016 2.0 I儀懧觺爛Lv 厪㏑'`IIg N5-l?\'VvU/歂鯯x懩~T85mg/m2 )1.FDA魦ffN-厤悢^莡(u誰 2.觺魐爛LvNCCNcWS2016 version2260mg/m2 ivd q3w:1.FDAyb芉T€TaS聰(u嶯籰梪@\钀Zfgbl忹y'`^\苸迉簚Lv剉N縹籰梪 2.NCCN ^\苸迉簚Lv2016.V4 餷"}^ ~ } Y^騼 ^X["20mg 40mg 60mg 80mg @\钀Zfg4Y垬钀逌秗苸迉Lv0 T€Tz樎0l?\'VvUO(u剉3hT筫Hh-NY壷N[?5mg/m2 ,{N)Y賬o Y 亾忚l鰁魰N\嶯1\鰁 g1. NCCN4Y垬钀縺$v(2016.V2.0) 2.FDA魦ffN 3.micromedex@╟P騠鄐US梑k峓岪l垟BR 440mg/20ml<[ HER23?`^\苸迉簚Lv>R!k峸傿R蠎:N4mg/kg 90R煍匭Y 亾廵Q0魚cBR蠎:N蟢hT2mg/kg 鍌R!k峸傿R蠎颯€譙 dkBR蠎颯嶯30R煍匭搹孾0b篘Y 佡~o 0齎NCCN^\苸迉簚LvcWS2016V4  0LN鳶諲N)Ynfm塠10NUOKQ鶴@?`OKQ0苸虄'`OKQ0Y$O'`OKQ0鏿$O'`OKQ 60NU/)Y'蟢!k1-2/e100000USMOLN鳶諲N蟢錯1-3!k v^颯9hnct^劅0莡秗怱_瀀螿0=1.錯,g魦ffN 2.-N齎%N蛻佉k莡/佉k'`OKQ籰梪cWS2014  3.%`'`猒痵p堩z-N齎%`蕥4N奮瀃鯈N禰qQ茓2016 micromedex-N*g6eU_佉k莡1-2N/kg 60-120N/)Y$\O:N^梱r_'`梑巔o (u嶯畍巔0n箄0h兓灩u0o僫r'`畍巔 oR鰯Q\舥剉籰梪0-4N(uMR (ump虄鑜\(u4l秐銐b5%秐瞞T擽(u0 8^(u蠎寑匭bY 佽l\N!k0.5-1g0 G1. 0謡畍(嵗o }{|o僫r4N奮擽(uc黐烻R 0 2. 0-N堺S觺T鹼邁o僫r籰梪n箄畍巔{|畍舥N禰qQ茓 02015 3. 04N奮蕥梪cWS畍舥N'`舥R孮 0f詋+Y歔600mg貧舥襨}徬憚vHBsAg3?`U[嘫 奩 ZZfgg(u,,g罷籰梪ba'`YN媁潃巔剉╟P傿R蠎:N600mg 蟢)YN!k 鉙g 橫RbTGW颯 N譙蹚邩q_蚑Q1. 0ba'`YN媁潃巔2柣lcWS(2015鬴癳Hr) 0 2. 0AASLD Guidelines for Treatment of Chronic Hepatitis B 01.齎FDA騗蟸yb芉噀蒪誰洀(u嶯b篘>yP`鏯莡 2.Stein MB, Pollack MH, Bystritsky A, et al.Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005; 177(3):280-288. 751.齎FDA*gyb芉)RfUS梑(u嶯籰梪b篘纎 }緰籰'`ba'`鹹iir梑縖;N舥 2. 02012 BCSH/BSBMTcWS:ba'`鹹iir梑縖;N舥剉蕥璭孴t 0 3. Kim SJ, Lee JW, Jung CW,et al.Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study[J].Haematologica.,2010, 95(11):1935-1942. 4. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, et al. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis[J]. Biol Blood Marrow Transplant.,2009,15(9):1005-1013. 71.齎FDA騗蟸yb芉噀蒪誰洀(u嶯b篘蔪P`湒峹 4O gbN4O g^:WP`鏯莡 2.Pollack MH, Lepola U, Koponen H, et al.A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007; 24(1):1-14. 71.pS魦ffN 2.-N齎%N蛻佉k莡/佉k'`OKQ籰梪cWS2014  3.Karnad DR1, Bhadade R, Verma PK et al.Intravenous administration of ulinastatin humanurinary trypsin inhibitor in severe sepsisa multicenter randomized controlled study.Intensive Care Med DO I 10.1007/s00134-014-3278-8 7厤o兞T魦ffN(uo冾vU_2017t^Hr  7^Nwo僨[O2017t^7g14錯pS裇  7Y鑜 1.FDA魦ffN颯(WFDA榌Q N N}http://www.fda.gov/ 2.,g顅U_臢汷;S梪:g刧耂€ 厤魦ffN(uo償^ cck膲Am z膲儭{t 3.+RT臢\O:N耂€ vQaIN(W嶯魦f鍕(u誰厤鶴哊購*NoT剉魦ffN v^N鉔h坴Q諲鴙 T?uT剉o兞TN齹(u嶯鍕(u誰0 7峇nfPN 7 20mg 100mg 70kx鉔kxx憼 7] ^W堾l 7^W堾l 7@l磏悥璑 7 m堾l 7@lnfaS臺)R 71 ~傴S塣憂fpQ 7 320mg 640mg 7Ⅺ ?fE<I=z?[A?C oH  擪稯 躊EbR裇:/U蟅8鏧P腪-腫 赲朸>`燼c`觗 oh )nn昽泀sXjt璾噖cy蕑a粈@+L >[|潗#D%F蕰枤SP鍧緸鯚蜖垺息娄 骚  VS娑欧*'L&zT4qK壳 笏缥yS裼A熤y?稼^|=蜣9濏^cc= PK!檗?[Content_Types].xml瑧薔?E鱄鼉?J湶@%閭菐洽|廊?韶钵UL襎B l,?鳛;鉹得槣B+$G]ミ7O侪V墎GA4攓Lx獪鈊$(^阞F?袪?啖H阿)R硨Lp!?袦習;蕝!蒔蠰祪? ?矾_毞0鏤??杵8蓔M?觚y!娧W>?w3D績pz颭飧jp桭嶩?S狁聺特Sj犂;潸￠熣n[溥诸|3蹅桙;'*鰅笓u核艠唆6灕{2cq痾[ミV猷?_绥睡腕r 昛w叾?絰舛怫皒8詫慬掖叮q5s(%?-嬦Q?皉p懤f\}@U<坬瓅輙麘蘄Ge\耏 {ikP?谠g[C$V粅l嘩鮬q)?s?璲鏴秡5' 糊fu-怨拐峢?:躂暤壨L^儱5∠A仌奏H痀32講二*堍璟<_妺d屒$鲬謠袵u悚"V褄豟戌?琕嶂襠還踶淭e?匽峤7馬羺g寳O?K蒖tZ蜁f€B湹 湠?衫隦窎楨p*a摸蘢6Y>鱢玃蘉侜軐X?(煸丩H祶elC肔?繰蜕士砠瀓t>)V??)缼甼蒬BBUuveD畚炬O儀|凢l*?竉??.ALE?puЛm鉁']趼锑?fY岓r玈慈d 7蔪?鈦n^賺rW扭?㏑??z? 壵宾@非#?韤 s˙YL镁€略羹卛*该69?m蝁&\i咠H艂忼(K& V削.K掑凩DU臅{D 甫黯軎氫e类N茻麨g?襇N5邷JV罱6吻&3(逯a有?E4謗;晦,/鲛?zb辠5姮8學秷V谬"\pkA銜f!xqQc, 畷慆!碂E魡:潲P[|坌 l 獥l銇t伌?h滌&M赎晈汾j舊})m攒%.袙澢4v贉轨淺糒cvlm荖55x鰀娐肖8菢/i誒^|?SΔ &鴮%0粜獝鼥葫PK!褠煻'theme/theme/_rels/themeManager.xml.rels剰M ?匃倃oo雍?輬协勪56?$Q祉?.嘺緳i粭澤c2?h:闀q毩m胳嶡RN壻;d癭値o7g慘(M&$R(.1榬'J摐袏T鶂?V?＆A然蠬鱱}狇|?絙{朠?除8塯/]As賲(⑵锑#洩L蔥汉倪PK-!檗?[Content_Types].xmlPK-!ブх6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!顸倦theme/theme/theme1.xmlPK-!褠煻' theme/theme/_rels/themeManager.xml.relsPK]  g2蓘 $颃U?CY慲 d褚MbP?_*+€%&ffffff?'ffffff?(?)?" d333333?333333?&<3U} L} L} L} L} `L} €L} @L}  L} `L} `L} L} L} @L} M}  M*€Aw€B€B€C'€C€C €C €C €C /€C '€C '€C €C€C€C€DF€CF€CF€CF€CF€C €B'€C €De€C'€CF€CF€C€CF€Ce€Ce€C _____________ ````````````` d ddd ddddd  d  d  dd ^ ^ ^ ^ ^ ^ ^ ^ ^  d  ^  ^  ^ N N N N N N^N N  N  N  N  N NN N N N N^N N  N  N  N  N! NN N" N# N$ N^N U%  N&  N'  N  N( N O) N* N+ N, N^N N-  N.  N/  N/  N( N0 N1 N* N2 N$ N^N N3  N4  N5  N  N! N0 N1 N* N2 N N^N N6 N7 N' N N( N0 N1 N* N2 N8 N^N N9 N: N' N N( N0 N1 N* N2 N; NNN N9 N< N' N N( N= N> N N? N@ NNN NA NB N' N N( NC ND N NE NF NNN NG NH N/ NI N( NJ NK NL NM NN NNN NO  NP  N/  N/  N( NQ NR N NS NT NNN NU  NV  N'  N  N( NW NX N NY NZ NNN N[  N\  N]  N^  N( N_ N` N Na NbN NcN Nd  Ne  N]  N  N( Nf Ng N Nh NiN NjN Nk  Nl  N]  N  N( Nm Nn N No NbN NpN Nq  Nr  N'  N  N( Ns Nt Nu Nv NiN NwN Nx  Ny  N'  N  N( Nz N{ N| N} N~ NNN N  N€  N'  N  N( Nz N{ N N} NN NN N  N  N'  N  N( N O O O N NNN N  N  N  N'  N( N N N N N NNN N  N  N'  N  N N N N N N NNN N  N  N'  N  N( N N N N N NNN N  N  N  N'  N( N N N N N NNN N  N  N  N'  N N N N No N NNN N  N  N'  N^  N( Nf Ng N Nh N NNN N  N  N'  N  N( N N N N N NNN N  N  N'  N  N( N N N N N NNN N  N  N'  N'  ND\l00h *€C!*F€C"*7€C#*€C$* €E%*'€F&*e€F'*€G(*€G)*€G**'€F+*e€D,*€G-*'€B.*e€H/*e€B0e€B1e€B2€B3F€F4€G5€F6€B7€B8€B9N €D:€B;€F<'€B=F€B>F€B?€B N N N N N NNN N N N N N( !N !N !N !NE !N !NN !N !N ! N ! N ! N' ! N( "N"N "N "N "N "NNN "N " N " N' " N' " N( #N #N #N* #N #N #N #NN #N # N # N # N # N( $N= $N> $N $N? $N $NNN $N $ N $ N $ N' $ N(@$CCCCCCCCCCCCCCCCCCCCCCCCCCCCC) %N %N %N %N %N %NNN %N % N % N' % N % N( &OJ &NK &N &N &N &NNN &N & N & N' & N & N( 'Om 'N 'O 'Oo 'N'N 'N'N 'N ' N ' N ' N' ' N( (Om (N (O (Oo (N (NNN (N ( N ( N ( N' ( N( )Pm )Q )P )Po )Q )QQQ )Q ) Q ) Q ) Q' ) Q( *N *N *N *No *N *NNN *N * N * N' * N * N( +N +N +N +N +N +NNN +N + N + N' + N' + N( ,Q ,Q ,Q ,Q ,QQ ,Q,Q ,Q , Q , QQQ -N -N -N -N -N -NNN -N - N - N - N - N( .N.N .N* .N .N .NNN .N . N . N' . N . N( /N  /N  /N /N  /N  /NNN /N / N / N' / N / N( 0N  0N  0N 0N  0N 0NNN 0N 0 N 0 N' 0 N 0 N( 1N  1N  1N* 1N  1N 1NNN 1N 1 N 1 N' 1 N 1 N( 2O 2N 2O 2Oh 2N 2N 2N2N 2N 2 N 2 N' 2 N 2 N( 3O 3N 3O 3Oh 3N 3N 3NN 3N 3 N 3 N' 3 N 3 N( 4O 4N 4O 4Oh 4O 4N 4NN 4N 4 N  4 N 4 N 4 N( 5O 5N 5O 5Oh 5O 5N 5N!5N 5N" 5 N# 5 N' 5 N 5 N( 6O 6N 6O 6Oh 6N$ 6N 6N%6N 6N& 6 N' 6 N' 6 N 6 N( 7O 7N 7O 7Oh 7N( 7N 7N7N 7N) 7 N* 7 N' 7 N 7 N( 8O 8N 8O 8Oh 8Ni 8N 8N+8N 8N, 8 N- 8 N' 8 N 8 N( 9N. 9N/ 9R0 9N1 9N2 9RNN 9N3 9 N4 9 N' 9 N' 9 R :S5 :Q6 :Q7 :Q8 :Q9 :QQQ :P: : Q; : Q< : Q= : Q> ;O0 ;O1 ;O* ;N? ;N@ ;NNN ;XA ; NB ; N' ; Y ; N( <N0 <N1 <NC <N? <ND <NNN <NE < NF < N' < N' < N( =TG =OH =O =OI =NJ =NNN =NK = NL = N' = N' = N( >TG >OH >O >OM >NN >NNN >NO > NP > N' > N' > N( ?TG ?OH ?O ?OI ?NQ?N ?NR?N ?NS ? NT ? N] ? Y ? N(Dl@F€BAe€FB'€FCe€BD€IEF€BF€BG'€FH€FI'€BJ€FKe€BL€FM€BNF€BO€BP€BQ€BR€BS€BT€BUF€BVF€GW€GX'€BY}€BZ€B[m €G\'€B]€B^'€B_'€B @TG @OH @O @OI @NU@N @NV@N @NW @ NX @ N] @ Y @ N( AOG AOH AOYAO AN( ANNN ANZ A N[ A N' A Y A N( BTs BOt BO\ BO] BN^BN BN_BN BN` B Na B N B N' B N CTs COt CO\ CO] CNbCN CNcCN CNd C Ne C N' C Y C N( DNf DNg DN* DNh DNi DNNN DNj D Nk D N' D N D N( EQ EQ EQ* EQ EQ EQQQ EQl E Qm E N' E Q E Q( FN FN FNC FNn FNo FNNN FNp F Nq F N' F N/ F N( GN GN GNC GNn GNr GNNN GNs G Nt G N' G N' G N( HNHN HN HNu HNv HNNN HNw H Nx H N H N' H N( INyIN INz IN{ IN| INNN IN} I Q~ I N' I N' I N( JNJN JN JN€ JN JNNN JN J N J N J N' J N KNKN KN KN€ KNvKN KNKN KN K N K N' K N K N( LNLN LN LN€ LN LNNN LN L N L N' L N L N( MNMN MN MN MN MNNN MN M N M N' M N M N( NN NN NN NN NN NNNN NN N N N N' N N N N( OZ OZ OZ ON OZ ONNN ON O Z O Z O N' O Z PZ PZ PZ PN PZ PNNN PN P Z P N' P N' P Z( QZ QZ QZ QN QZ QNNN QN Q Z Q Z Q N' Q Z( RZ RZ RZ RN RZ RNNN RN R Z R Z R N' R Z( SN SN SN* SN SNN SNSN SN S N S N' S N S N( TN TN TN* TN TNN TNTN TN T N T N' T N T N( U[ UN UN UNo UN UNNN UN U N U N' U N' U N( VNVN VN VN VN VNNN VN V N V N' V N V N WN WN WN WN WN WNNN WN W N W N W N' W N( XQ XQ XQ XQa XQXQ XQXQ XQ X Q X Q' X Q' X Q YN0 YN1 YN* YN2 YN YNNN YN Y N Y N' Y N Y N( ZNJ ZNK ZN ZN ZN ZNNN ZN Z N Z N' Z N Z N( [N [N [N [N [N [NNN [N [ N [ N' [ N' [ N( \Q \Q \Q \Q \Q \QQQ \Q \ Q \ Q' \ Q \ Q( ]N ]N ]N* ]N ]N ]NNN ]N ] N ] N' ] N ] N( ^N ^N ^N ^N ^N ^NNN ^N ^ N ^ N' ^ N' ^ N( _N _N _N _N _N _NNN _N _ N _ N' _ N' _ N(DJl`€Bab€BbC€Hc€BdF€Bee€Gf/€Hg€Bh €Bim €Bj€Bk€Bl'€Bm€BnF€Ho'€CpN €Cq€Cr €Cs€Gtm u€Bve€Bw€Bx€By €Bz€B{€B|€B}€B~€B  `N `N `N* `N `N `NNN `N ` N ` N ` N' ` N( aN aN aN* aN aN aNNN aN a N a N' a N a N( bN bN bN* bN bN bNNN bN b N b N b N b N( cN cN cN cNa cN cNNN cN c N c N c N c N( dN dT dN dN dN dTTT dO d N d TTT eN eN eN eN8 eN eNNN eN e N e N' e N e N( fN fN fN fN fN fNNN fN f N f N' f N f N( gN gN gN* gN gN gNNN gN g N g Q' g Q g Q( hOhN hO hO hN hNNN hN h N h N h N' h N( iOiN iO iO iN iNNN iN i N i N i N' i N( jNjN jN jNo jNv jNNN jN  j N  j N j O j N( kOkN kO kOo kN  kNNN kN  k N  k N k N' k N( lN lN lN lN8 lN lNNN lN l N l N' l N l N( mN mN mN mN mN mNNN mN m N m N' m N m N( nN nN nN* nN nN nNNN nN n N n N' n N n N( oN oN oN oN  oN! oNNN oN" o N# o N' o N o N pN$ pN% pN pN8 pN& pNNN pN' p N( p Q) p N) p N( qN* qN+ qN qN, qN qNNN qN- q N. q N' q N q N( rR/rR rR rR? rR0 rRNN rR1 r N2 r N' r N r N( sN3sN sN sNh sN4 sNNN sN5 s N6 s N' s N s N( tN7 tN8 tN tN9 tN: tO\\ tN; t N< t N' t N t N( uN=uN uN uN> uN uNNN uN? u N@ u N' u N' u N( vN=vN vN vN> vNA vNNN vNB v NC v N' v N v N( wNDwN wNY wNE wNF wNNN wNG w NH w N' w N' w N( xNDxN xNY xNE xNixN xNIxN xNJ x NK x N' x N x N( yNDyN yN* yNL yNM yNNN yNN y NO y N' y N y N( zNPzN zN zN8 zN zNNN zNQ z NR z N z N' z N( {NP{N {N {N8 {N  {NNN {NQ { NS { N { N { N( |NP|N |N |N8 |NT |NNN |NU | NV | N | NW | N( }NP}N }N }N8 }NX }NNN }NY } NZ } N } N } N( ~N[~N ~N ~N ~N ~NNN ~N\ ~ N] ~ N ~ N' ~ N N^N N N_ Nb NNN N`  Na  N'  N'  N(Dl€e€J€KF/e@ €N €Nb €N €N €N €NNN €Nc € Nd € N' € N € N( Nf N N Nh Ne NNN Nf Ng N' N N( N5 Nh N N8 Ni NNN Nj Nk N' N N( Q Q Q Q Q  QQQ Ql Qm Q' Q Q( Nf Nn N No Np NNN Nq Nr N' N N( ]s ]t Qu Qv Qw Qx Qy Pz Qx Q{ Q Q Q( O| O} Nu N~ O O€ OO O N O OO O| O} Nu N~ O O OO O N O OO WR Nu R W RRR W N O OO VR N R VV VV V N N' N N( abbbbbbbbbbbc 6>@dbbA :     7J**猩陏寕K O0W^ Sheet2!C339Jmm猩陏寕K  O藌f穅 Sheet2!C331ggD ?鄥燆鵒h珣+'迟0px  wuWindows 用户1Microsoft Excel@&鮙搲@`O闍p@?胀諟.摋+,D胀諟.摋+,p,  DocumentSummaryInformation8CompObj h  终版 工作表$([c _PID_HLINKSKSOProductBuildVerA po Sheet2!C331po Sheet2!C3392052-10.1.0.6554?  FMicrosoft Excel 2003 工作表Biff8Excel.Sheet.8?瞦